WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 2 fonti

Pfizer CEO Bourla reconsiders German investments as industry takes aim at healthcare reform plan: Reuters

Germany’s new healthcare reform initiative has already led two global drugmakers to slice their planned investments in the country. | The CEO voiced his concerns about Germany's new healthcare reform plan in a letter to Chancellor Friedrich Merz, according to reports.

Raccontata dazeit.defiercepharma.com

Confronto fonti

2 prospettive sulla stessa storia
AI · summaries
fiercepharma.comStai leggendo3 g fa

Pfizer CEO Bourla reconsiders German investments as industry takes aim at healthcare reform plan: Reuters

Germany’s new healthcare reform initiative has already led two global drugmakers to slice their planned investments in the country. | The CEO voiced his concerns about Germany's new healthcare reform plan in a letter to…

originale
zeit.de3 g fa

Pharmaindustrie: Pfizer hinterfragt geplante Investitionen in Deutschland

Nach Eli Lilly und Boehringer Ingelheim überdenkt auch Pfizer seine Investitionen in Deutschland. Ein Treffen mit dem Bundeskanzler im Herbst sagte der Konzernchef ab.

Leggi questa versione →

Timeline cronologica

  1. mercoledì 10 giugno 2026·zeit.de

    Pharmabranche: Pfizer-Chef sagt Merz ab und stellt Investitionen in Frage

    Hier finden Sie Informationen zu dem Thema „Pharmabranche“. Lesen Sie jetzt „Pfizer-Chef sagt Merz ab und stellt Investitionen in Frage“.

  2. mercoledì 10 giugno 2026·zeit.de

    Pharmaindustrie: Pfizer hinterfragt geplante Investitionen in Deutschland

    Nach Eli Lilly und Boehringer Ingelheim überdenkt auch Pfizer seine Investitionen in Deutschland. Ein Treffen mit dem Bundeskanzler im Herbst sagte der Konzernchef ab.

originale
  • mercoledì 10 giugno 2026·fiercepharma.com

    Pfizer CEO Bourla reconsiders German investments as industry takes aim at healthcare reform plan: Reuters

    Germany’s new healthcare reform initiative has already led two global drugmakers to slice their planned investments in the country. | The CEO voiced his concerns about Germany's…

  • giovedì 11 giugno 2026·fiercepharma.com

    Joint initiative of 5 EU countries calls for 'unified approach' to pharma framework amid US drug pricing pressure

    With drug pricing pressure building from the U.S., a healthcare-focused consortium of five European countries are calling for a “unified approach” to strengthen Europe’s…